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Abstract IL-33, a member of the IL-1 cytokine family and a
ligand to receptor ST2, has great potential to induce a T helper
2-type inflammatory response. IL-33 is proven to be released
by epithelial cells during their injury by different environmental
stimuli such as airborne allergens, viruses, and air pollutants.
IL-33 acting as an endogenous danger signal is termed an
alarmin. As such, this cytokine is considered to play a crucial
role in an allergic inflammatory disease such as rhinitis.
Recent investigations regarding the IL-33/ST2 axis involve-
ment in Th2 inflammatory response and pathogenesis of rhinitis
have been reviewed. The role of IL-33 as a novel promising
therapeutic target has also been discussed.
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Introduction
IL-33 is a member of the IL-1 family of cytokines, such as
IL-1β and IL-18. IL-33 is also known as a member of
mesenchymal-derived cytokines such as IL-25, thymic stro-
mal lymphopoietin (TSLP). IL-33 is an interesting cytokine
because of it has either proinflammatory or anti-inflammatory
properties. IL-33 is believed to be involved in Th2-mediated
inflammatory responses in allergic diseases such as asthma,
anaphylaxis, and atopic dermatitis, and in host defense against
parasites. On the other hand, IL-33 has a protective effect in
atherosclerosis, obesity, type 2 diabetes, and cardiac remodel-
ing [1]. Moreover, IL-33 is thought to be a bridge between
innate and acquire immune defences [2•].
IL-33 was originally identified as “DVS27” and as a
nuclear factor protein in high endothelial venules; thus,
it was called NF-HEV [3, 4]. As a result of searching
for the sequences containing a β-trefoil structure, it has
been termed as IL-33 and qualifies as a member of the
IL-1 cytokine family [5]. The first report describing this
protein as IL-33 came from 2005; that is why our
understanding of the role and function of this cytokine
is still evolving [5].
Stimulation of IL-33 Release and its Activation
IL-33 may be released by epithelial cells during their injury
or necrosis caused by exogenous triggers such as mechani-
cal trauma, viruses, smoke, airborne allergens, or endoge-
nous triggers. These triggers may also lead to activation of
pattern recognition receptors such as TLRs, and as a
consequence, the release of IL-33 from epithelial cells
[2•]. The fact that necrotic cells release uncleaved but
biologically active IL-33 [2•] suggests that IL-33 may
act as a endogenous danger signal; thus, it has been
termed an alarmin [2•, 6, 7].
Similarly to IL-1β and IL-18, IL-33 is proteolytically
cleaved by caspases. However, the former cytokines are
activated in inflammasome during apoptosis and their
cleaved forms become biologically active and secreted [8].
In contrast, full-length IL-33 passively secreted by necrotic
cells is biologically active in vivo and proteolysis by
caspase-1 from apoptotic cells suppresses or even inacti-
vates IL-33 bioactivity [9–11, 12•]. Thus, apoptotic cells
inactivate IL-33 and prevent the development of type 2
immune responses.
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Receptor for IL-33
IL-33 is a ligand for a heterodimeric membrane-bound re-
ceptor consisting of the orphan IL-1 family receptor ST2
(suppression of tumorigenecity 2), also called ST2L, T1,
Der-4 and fit-1, and the ubiquitously expressed IL-1
receptor-accessory protein IL-1RAcP, whereas ST2 expres-
sion is restricted to IL-33 stimulation [5, 13].
IL-33 acts through activation of the ST2L receptor com-
plex, but also as an intracellular nuclear factor with tran-
scriptional regulatory/repressing properties [14, 15]. There
are at least three isoforms of ST2 gene production, resulting
from different splicing of the gene, a soluble form of ST2
(sST2), a membrane-bound form (ST2L), and a constitutive-
ly active variant ST2 (ST2V) [2•, 16, 17]. Soluble ST2 acts
as a decoy receptor for IL-33 and functionally inhibits IL-33
activity in vitro and in vivo [18].
Many cells express ST2L receptor for IL-33. ST2L is
expressed on the earliest human progenitors cells such as
CD34+ cells and on the multiple stages of development of
leukocytes. Moderate levels of ST2L are expressed on rest-
ing eosinophils, which increased in the airways of mice with
OVA- induced asthma. ST2 is expressed on Th2 cells, but
not Th1 cells [19–21]. Similarly, ST2 is expressed on in
vitro skewed Tc2 cells rather than Tc1 cells [22]. The
expression of ST2 was also found in mast cells, basophils,
macrophages, human and mouse iNKT cells, NK cells and
B-1 cells, but not in neutrophils [2•, 23, 24].
Elevated serum level of ST2 was found in adults and
children with acute exacerbation of asthma but not in sea-
sonal allergic rhinitis patients [25–27]. However, expression
of ST2 was significantly higher in the nasal epithelium in
allergic rhinitis patients [28].
Cellular Source of IL-33
IL-33 is constitutively expressed on plenty of cells and
multiple tissues, among them by epithelial barrier tissues,
such as nasal, bronchial or ocular epithelial cells, human and
mouse mast cells derived from peripheral blood or cord
blood progenitor cells, lymphoid organs, brain, embryos,
inflamed tissues, smooth muscle cells, keratinocytes, macro-
phages and dendritic cells, and others [28–32].
Activity of IL-33 in Cells Participating in Allergic
Inflammation
IL-33 has a plenipotent and pleiotropic activity. This cyto-
kine is expressed and acts on many cells participating in
allergic inflammation such as antigen-experienced Th2
cells, mast cells, eosinophils, basophils, dendritic cells, and
CD34+ stem cells, and induces Th2-type cytokine pro-
duction by different cells; thus, these facts make a base
for the assumption that IL-33 may play an important
role in the pathogenesis of allergic inflammation such as
allergic rhinitis [24, 33].
Mast Cells
IL-33 alone or together with TSLP directly acts upon mature
as well as precursor human mast cells [34]. IL-33 is able to
induce the release of proinflammatory cytokines in bone
marrow-derived mast cells [29, 35]. IL-33 activates mast
cells as a result of its release from injured structural cells.
Mast cells through ST2 receptor recognize IL-33, and sig-
naling pathways are started with subsequent activation of
NFκB and transcription of proinflammatory cytokines such
as interleukins IL-1β, IL-6, IL-8, IL-13, TNF, chemokines,
and prostaglandins [12•]. IL-33 may induce cytokine pro-
duction in either the presence or absence of co-stimulation
of mast cells via IgE/antigen–FεRI signals [35, 36]. IL-33
primes mast cells for activation by IgG immune complexes,
and enhances its survival and adhesion [37].
Basophils
IL-33 also exerts distinct effects on basophils. IL-33/ST2
interactions enhanced degranulation in response to IgE
cross-linking stimuli and enhanced basophil migration to
eotaxin without effect on surface expression of CCR3 [22,
24]. Moreover, IL-33 synergizes with IL-3 to promote IL-4
production and CD11b expression by basophils, enhancing
basophil adhesiveness [2•, 24]. Similarly to mast cells, hu-
man blood-derived basophils responded to IL-33 via ST2
receptor and as a result produce pro-inflammatory cytokines
such as IL-1β, IL-4, IL-5, IL-6, IL-8, IL-13, and granulo-
cyte macrophage colony-stimulating factor [24, 38, 39].
T Cells
IL-33 induces Th2 cytokine production and chemotaxis of
in vitro polarized Th2 cells [5, 12•, 40]. In mouse airways,
antigen-specific Th2 cells stimulated with IL-33 preferen-
tially induce production of IL-5 and IL-13, but not IL-4,
thus these T cells are called atypical Th2 cells [41•]. Similar
results were obtained in BAL fluid after intra-nasal admin-
istration of IL-33 in which IL-5 and IL-13 levels increased
and IL-4 did not change, suggesting that IL-33 may be
involved in IL-4-independent Th2 cell differentiation [13].
IL-33 enhances IL-5 and IL-13 and, interestingly, IFN-
gamma production by human Th2 in vitro skewed cells in
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HDM-specific T cell culture. IL-33 was found to be in-
volved in the mechanism of Th2 response to house dust
mite allergens in experimental model of asthma and to
peanut allergens in experimental model of food allergy and
anaphylaxis [42]. However, in ST2-deficient and IL-33-
deficient mice, normal Th2 cells differentiation was ob-
served [43, 44]. Moreover, iNKT cells express ST2L recep-
tor and IL-33 stimulates the production of both type 1 and
type 2 cytokines [24]. Thus, IL-33 promotes a Th2-type
response and under certain conditions a Th1-type response
as well.
Eosinophils
IL-33 mediates blood eosinophilia and eosinophil airway
inflammation in mice [45]. It stimulates eosinophils differ-
entiation from CD117+ progenitors in an IL-5-dependent
manner. In humans, it enhances eosinophils survival,
upregulates cell surface expression of adhesion molecule
ICAM-1 on eosinophils, and suppresses ICAM-3 and selec-
tin. IL-33 mediates significant release of the proinflamma-
tory cytokine IL-6 and the chemokines CXCL8 and CCL2
and enhances Siglec-8-mediated apoptosis of eosinophils
[46, 47]. In mice treated with IL-33, increased expression
of CCR3 and CCR4 and their ligands, CCL11, CCL17, and
CCL22, implicated in eosinophils chemotaxis in lung tissue
was observed [13]. In knock-out IL-33 mice, eosinophils
infiltration and cytokine production were reduced [13].
IL-33 stimulates eosinophils superoxide production and de-
granulation [48]. In humans, a correlation between blood
and pulmonary eosinophilia with elevated IL-33 serum level
was found [49].
IL-33 and Allergic Rhinitis
The plenipotent and pleiotropic activity of IL-33 in immune
reactivity skewed into the Th2-type highlights the role of
this protein in allergy. The pathogenesis of allergic rhinitis is
driven by Th2-type immune response. Thus, the pertinence
of IL-33 in this disorder can be safely assumed. There have
been recently published papers which support the clinical
relevance of this notion.
The results of our study concerning the issue showed
elevated IL-33 serum level in patients with intermittent
allergic rhinitis sensitive to tree and/or grass pollen. The
increased level of this protein was comparable with that
observed in asthma patients. Moreover, the elevated level
of this protein was correlated with the severity of rhinitis
symptoms, suggesting the role of this protein in the patho-
physiology of this disorder. However, unexpectedly, ST2
serum level was in the same range as in healthy controls
and in patients suffering from asthma [27]. It is notable the
asthma patients included in the study were in the stable
phase of the disease; the symptoms were well-controlled
by low doses of inhaled corticosteroids and short and/or
long acting b2-mimetics.
As presented above, IL-33 mediates its biological effects
via interactions with a receptor consisting of two components,
ST2 and IL-1 receptor accessory protein. The ST2/IL-33
pathway is associated with Th2-type pathology both in the
promotion and maintenance of allergic inflammation. On the
other hand, soluble ST2 being essential for the function of
IL-33 acts as a decoy receptor for IL-33 bioactivities [50].
These data explain, at least to some extent, the discrepancy
between ST2 and IL-33 serum level in our patients. Impor-
tantly, the results of other studies have demonstrated signifi-
cant increases in the ST2 serum level in asthma exacerbation
episodes both in adults and children [25, 26].
Regarding these observations, one can assume that solu-
ble ST2-dependent regulation of IL-33 bioactivity occurs in
intense airway inflammation. It is the most profound feature
of symptomatic asthma but not rhinitis.
Our data remain in agreement with the observation of
Sakashita et al. [51] indicating significant increased serum
levels of IL-33 in patients suffering from intermittent aller-
gic rhinitis caused by Japanese cedar pollen sensitization.
The higher levels of IL-33 in nasal secretions from house
dust mite-sensitive patients with perennial allergic rhinitis
was observed [52]. Moreover, the genetic polymorphism in
ST2 and IL-33 has been proved in rhinitis [5, 18]. These
data further support the concept of the role of a ST2/IL-33
axis in the pathogenesis of this disorder.
The role of IL-33 in rhinitis was also pointed out in an
excellent study published by Haenuki et al. [35]. They
proved in an experimental study performed in a murine
model that IL-33 constitutively expressed in nasal epithelial
cells is released after allergen exposure. The diminished
IL-33 expression after exposure to allergen was associated
with the increase of this protein in nasal lavage fluid. This
justifies the measuring of IL-33 levels in nasal lavage fluid
after allergen provocation as a marker of this pathology. In
allergen-immunized allergen-challenged IL-33−/− mice ,
significant diminishment in sneezing and accumulation of
eosinophils and basophils in the nasal mucosa, parallel with
the reduction in specific IgE response, was proved. Further-
more, histological examinations revealed only slight, if any,
changes in the IL-33−/− mice after allergen provocation. On
the contrary, both early and late phase reactions relevant for
rhinitis symptoms were markedly developed in allergen-
immunized and then allergen-challenged IL-33+/+ mice.
These results evidenced the contribution of IL-33 in the
pathogenesis of rhinitis. It is important because the
allergen-specific murine model mimics the main character-
istics of human rhinitis. Significant upregulation of IL-33
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mRNA expression in inflamed nasal epithelial cells of
patients with intermittent allergic rhinitis during pollen sea-
son was observed, as in the allergic rhinitis murine model.
Prompt IL-33 release from the epithelial cells upon allergen
exposure is essential for allergic rhinitis symptoms, through
the bioactivity of the histamine released from the mast cells
after cross-linkage of FceRI with allergen-specific IgE and
infiltration of eosinophils/basophils and mastocytes in the
nasal mucosa as in the site of allergen challenge. The ongoing
inflammation process is directly responsible for the late phase
reaction and the chronic symptoms of the disease. This also
applies to allergic rhinitis. In turn, cytokines produced by
IL-33- stimulated Th2 cells can induce goblet cells hyperpla-
sia which might lead to the irreversible mucosal hypertrophy
also seen in patients with allergic rhinitis [12•, 35].
IL-33 functioning as an “alarmin”, secreted following ep-
ithelial damage from different pathogens, plays a central role
in the Th2 cytokine-mediated eosinophilic inflammation. As
such, IL-33 is implicated in allergic respiratory pathology, not
only for rhinitis but also for asthma [6, 7, 12•, 53].
Important data with plausible significant potential of this
protein for human pathology have been presented by other
authors. Anti-IL-33 antibody was found to be effective in
suppression of symptoms of the mouse model ovalbumin-
induced allergic rhinitis. The therapeutic effect of the anti–
IL-33 antibody in experimental allergic rhinitis (non–
scratching behavior) was confirmed by the decreased eosin-
ophilic infiltration in the nasal mucosa, with a decrease in
the number of eosinophils as well as the titers of IL-4, IL-5,
and IL-13 cytokines in BAL fluid [54•]. Similar results were
obtained in a soluble form of ST2-treated animals in such a
model [55]. On the other hand, intra-nasal administration of
IL-33 triggers allergic inflammation evolvement in the air-
ways [13]. Liu et al. [56] showed, in the murine model of
allergic asthma, the potential of a rabbit polyclonal antibody
against IL-33 to inhibit airway inflammation. It is particu-
larly important in the light of the recently proposed “united
airway disease” concept.
These data further speak for the profound ability of anti–
IL-33 to suppress allergic inflammation ongoing in target
organs and to be responsible for allergy symptoms. The
results presented allow a belief in the potential applicability
of this type of treatment in human respiratory allergies.
Discussing the role of IL-33 in airway allergy, it is worth
mentioning the results of the study in the animal model
which showed the association of IL-33 polymorphism with
asthma but, against expectations, not atopy [57]. These
observations are consistent with findings of other authors
depicting no difference in IL-33 serum level between atopic
and nonatopic asthma [58]. It remains in line with the
characteristic of the IL-33 bioactivity. This cytokine is able
to induce and maintain IgE-dependent inflammatory reac-
tion in the absence of a specific allergen. It markedly
corresponds with the evidence of IL-33 playing a crucial
role in the innate eosinophilic airway inflammation, but not
in acquired immune responses such as IgE production [45].
An elegant experimental mice model of allergic rhinitis
discussed above [35] provides further an important insight
into the role of IL-33 in an IgE-mediated immune response
and allergic symptoms development. The allergen challenge
of allergen-immunized IL-33−/− mice causes a considerable
increase of total IgE level, but not rhinitis symptoms. The
IL-33−/−mice evidenced elevated serum IgE concentrations
in the immunization phase, but a simultaneously reduced
capacity to increase IgE response on allergen challenge.
Thus, these results indicate that IL-33 has substantial role
in the allergic inflammation development in the nasal mu-
cosa closely related to the symptoms of the disease. Simul-
taneously, they proved that the role of IL-33 in the IgE
production is dispensable [59]. Recruitment of inflammato-
ry cells, mast cells, eosinophils, and basophils as well as
Th2 cells into nasal mucosa is critical for rhinitis symptoms,
particularly for its chronicity. In this process, IL-33 plays a
substantial role, acting as a potent Th2 chemoattractant and
stimulator of FceRI cells to release chemoattractant substan-
ces for eosinophils/basophils.
Although a limited number of exogenous and endoge-
nous agents are capable of inducing Th2 (eliciting pro-TH2
gene expression) by epithelial cells, many cases of asthma
and/or rhinitis are in nonatopic conditions. Proving the role
of IL-33/ST2 as a signal to the mast cells degranulation in
the absence of specific allergen explains these observations,
at least to some extent [60].
IL-33 seems to be an increasingly useful marker of Th2-
mediated diseases such as allergic rhinitis and bronchial asth-
ma, although not of a specific character. IL-33 is produced by
epithelial cells when they become injured or necrotic [7]. So
IL-33 could be viewed as a marker of tissue injury, particularly
in epithelial and/or endothelial cells which are directly ex-
posed to environmental stimuli [6, 16]. The question is wheth-
er an allergen is able to cause necrosis and/or injury of the
epithelial cells? It might be the case with regard to allergens
having enzymatic activity. Further studies are needed to con-
clusively answer this question.
Nevertheless, there are data showing that inhalation of
papain or house dust mites can cause airway inflammation
without prior sensitization. This phenomenon is associated
with increased IL-33 mRNA expression in the absence of
acquired immune cells. The same is observed after admin-
istration of recombinant IL-33 [12•, 61].
Conclusions
Observations regarding the role of IL-33 in disturbed im-
mune regulation provide novel insights into the mechanism
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of allergic diseases. IL-33 is released by many cells during
tissue injury upon proinflammatory stimulation, promoting
the severity of allergies.
The increase level/activity of IL–33 in allergic disorders
and its correlation with disease severity on the one hand and,
on the other hand, the effectiveness both of an anti-IL-33
antibody and a soluble form of ST2 in alleviating signs and
symptoms of ovalbumin-induced allergic rhinitis/asthma in
an animal model justify the view of IL-33 as a potential
therapeutic target in allergic disease.
It is important that the antihistamines commonly applied
in the treatment of allergic rhinitis are potent to down-
regulate the expression of IL-5 mRNA and histamine H1-
receptor gene expression, but not that of IL-33 mRNA in the
mucosa of the respiratory tract [62]. There is a similar case
with regard to the corticosteroids, the drugs of first choice
both in the treatment of allergic rhinitis and asthma. Cortico-
steroids exert their activity only partially on IL-33-mediated
immune reaction [63].
One can assume that the down-regulation of IL-33 gene
expression in the nasal mucosa provides the basis for a
better therapeutic effect of allergic rhinitis treated with anti-
histamines and/or corticosteroids.
This therapeutic concept is particularly attractive in the
light of the observations of the baseline IL-33 mRNA ex-
pression in epithelial cells derived from chronic rhinosinu-
sitis with nasal polyps, which was several times higher in
recalcitrant patients than in those with responsive disease
[64•]. In the light of these data, anti-IL-33 therapy seems to
be particularly promising. These findings can be extrapolat-
ed to rhinitis and/or asthma, especially to those forms which
are not sufficiently responsive to recently applied treatment,
although there is a need for further conclusive research.
IL-33 is a potent proinflammatory cytokine activated in
allergen- and non-allergen-dependent fashion. Its role is
more potent in the elicitation phase of allergic reaction than
in the sensitization phase. One might believe that the
IL-33/ST2 pathway is particularly important for inflamma-
tion development in the late phase response. The results of
the study performed in allergen-immunized mice with the use
of recombinant human ST2-Fc (receptor of IL-33) chimera
protein are encouraging [65].
Thus, considering the IL-33/ST2 pathway as a therapeu-
tic target should be of particular importance. In this context,
it is reasonable to believe in IL-33 as a novel therapeutic
target for allergic disorders, not only in allergic rhinitis but
also or even especially in asthma, which remains treatable
but not curable until now due to a sustained inflammation
process in the airway.
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